Gilde Healthcare anchors $103.5 million public offering by Affimed - Gilde Healthcare

Gilde Healthcare anchors $103.5 million public offering by Affimed

April 21, 2022
Utrecht (the Netherlands)

Gilde announces that it acted as anchor investor in an upsized $103.5 million public offering by German immune-oncology company Affimed N.V. (Nasdaq: AFMD) (“Affimed”). As a result, Gilde’s ownership exceeds 5% of the outstanding share capital of Affimed.

“We are excited to team up with the excellent team at Affimed, who are front-runners in engaging the innate immune system to fight some of the most difficult-to-treat cancers,” said Joep Muijrers, General Partner at Gilde Healthcare and responsible for Gilde’s public investment franchise. “We are proud to add Affimed to our expanding portfolio, and look forward to closely working with them in the years to come”.

Pieter van der Meer, Managing Partner of Gilde Healthcare commented “We followed Affimed for many years and are convinced about the potential of its technology platform and immune oncology product pipeline. By anchoring the public offering we enabled a transformational financing in a turbulent market environment, reflecting our impactful, hands-on investment strategy.”

The full text of the announcement from Affimed can be found here:
Affimed announces closing of public offering of common shares and full exercise of underwriters’ option to purchase additional shares – Affimed.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor with two fund strategies: Venture&Growth and Private Equity. The firm operates out of offices in Utrecht (The Netherlands), Frankfurt (Germany) and Cambridge (United States). Gilde Healthcare Venture&Growth invests in fast growing, innovative companies active in (bio)pharmaceuticals, healthtech and medtech that are based in Europe and North America. For more information, please visit www.gildehealthcare.com.

Gilde Healthcare announces successful sale of health-it software company Performation to Enovation, part of Legrand

Exit confirms Gilde Healthcare's investment strategy of building market-leading healthcare companies that deliver better care at lower cost Under ownership of Gilde Healthcare’s private equity fund, Performation has evolved into a leading European SaaS healthcare...
February 13, 2025

Gilde Healthcare company NIZO participates in national consortium investing in precision fermentation scale-up facility

The Netherlands is strengthening its position as a global leader in cellular agriculture with the launch of two independent, open-access scale-up facilities. These facilities, developed in a collaboration between NIZO Food Research, Cultivate at Scale...
February 4, 2025

Gilde Healthcare company GT Medical Technologies raises $37 million in to advance GammaTile® for patients with operable brain tumors

GT Medical Technologies, Inc. (GT MedTech), a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced the company has completed a $37 million first close of...
January 17, 2025